Insider Selling: Regeneron Pharmaceuticals (NASDAQ:REGN) EVP Sells 1,131 Shares of Stock

Key Points

• Regeneron EVP Marion Mccourt sold 1,131 shares at an average $857.39, totaling approximately $969,708. The transaction was conducted under a pre-arranged Rule 10b5-1 plan and reduced her holdings by 8.61%.
• REGN shares fell 1.0% to $843.47, near the company’s 52-week high of $859.34. Regeneron recently exceeded quarterly earnings and revenue estimates, reporting $14.29 in EPS and $4.29 billion in revenue.
• Analysts maintain a “Moderate Buy” consensus, with 14 Buy ratings and 10 Holds, although the average price target of $800.36 is below the current share price. Institutional investors and hedge funds own 83.31% of the stock.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Get Free Report) EVP Marion Mccourt sold 1,131 shares of the business's stock in a transaction on Thursday, September 3rd. The shares were sold at an average price of $857.39, for a total transaction of $969,708.09. Following the completion of the transaction, the executive vice president directly owned 12,003 shares of the company's stock, valued at $10,291,252.17. This trade represents a 8.61% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Marion Mccourt also recently made the following trade(s):

• On Wednesday, September 2nd, Marion Mccourt sold 1,215 shares of Regeneron Pharmaceuticals stock. The stock was sold at an average price of $850.00, for a total value of $1,032,750.00.

Regeneron Pharmaceuticals Trading Down 1.0%

REGN stock traded down $8.56 during midday trading on Thursday, hitting $843.47. 496,170 shares of the company's stock were exchanged, compared to its average volume of 839,664. The stock's fifty day moving average price is $729.93 and its 200-day moving average price is $719.06. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.78 and a current ratio of 3.34. The company has a market cap of $86.84 billion, a PE ratio of 20.85, a price-to-earnings-growth ratio of 1.61 and a beta of 0.19. Regeneron Pharmaceuticals, Inc. has a one year low of $541.00 and a one year high of $859.34.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $10.16 by $4.13. The company had revenue of $4.29 billion during the quarter, compared to the consensus estimate of $3.82 billion. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The company's revenue for the quarter was up 16.7% compared to the same quarter last year. During the same period in the prior year, the company earned $12.81 earnings per share. Research analysts predict that Regeneron Pharmaceuticals, Inc. will post 44.25 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, August 31st. Investors of record on Tuesday, August 18th were given a $0.94 dividend. The ex-dividend date was Tuesday, August 18th. This represents a $3.76 annualized dividend and a dividend yield of 0.4%. Regeneron Pharmaceuticals's payout ratio is currently 9.29%.

Analyst Upgrades and Downgrades

Several analysts have commented on REGN shares. HSBC dropped their target price on shares of Regeneron Pharmaceuticals from $990.00 to $880.00 and set a "buy" rating on the stock in a report on Monday, July 6th. Piper Sandler reduced their price target on shares of Regeneron Pharmaceuticals from $855.00 to $854.00 and set an "overweight" rating for the company in a report on Thursday, July 9th. Wells Fargo & Company raised their price objective on shares of Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the stock an "equal weight" rating in a report on Friday, July 31st. Cantor Fitzgerald raised their price objective on shares of Regeneron Pharmaceuticals from $750.00 to $795.00 and gave the stock an "overweight" rating in a report on Friday, July 31st. Finally, Guggenheim boosted their price objective on shares of Regeneron Pharmaceuticals from $1,000.00 to $1,030.00 and gave the company a "buy" rating in a research report on Monday, August 3rd. Fourteen analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $800.36.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Large investors have recently bought and sold shares of the company. SHP Wealth Management bought a new position in shares of Regeneron Pharmaceuticals during the 4th quarter worth approximately $26,000. Western Wealth Management LLC bought a new stake in shares of Regeneron Pharmaceuticals in the first quarter worth $26,000. Titan Wealth CI Ltd acquired a new position in Regeneron Pharmaceuticals during the fourth quarter worth $29,000. Mowery & Schoenfeld Wealth Management LLC acquired a new position in Regeneron Pharmaceuticals during the second quarter worth $29,000. Finally, Trust Co. of Vermont bought a new position in Regeneron Pharmaceuticals in the second quarter valued at $29,000. Institutional investors and hedge funds own 83.31% of the company's stock.

More Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron reported completion of a Phase 1/2 study evaluating its cemiplimab (Libtayo) combination with SNS-101. The update advances a potential oncology program, although no new efficacy results were disclosed. Regeneron’s Cemiplimab Combo Trial With SNS-101 Reaches Completion
• Neutral Sentiment: A market report projects continued growth in the global complement-inhibitors market through 2035 and lists Regeneron among the major industry participants, supporting the company’s longer-term opportunity but offering no company-specific financial update. 2026 Complement Inhibitors Market Analysis Report
• Neutral Sentiment: Analysts remain moderately optimistic about REGN’s outlook, with coverage highlighting its recent outperformance versus the broader healthcare sector. Regeneron Pharmaceuticals Stock: Is REGN Outperforming the Healthcare Sector?
• Negative Sentiment: Multiple law firms are publicizing a securities class action focused on Regeneron’s Phase 3 Fianlimab-Libtayo melanoma trial. The lawsuit alleges that the company’s disclosures about slowing event accrual and the trial protocol understated the risk of failing the primary endpoint; the trial ultimately failed, undermining earlier positive trial-risk messaging. Investors who purchased shares during the alleged class period may seek lead-plaintiff status by September 14, 2026. Hagens Berman Regeneron Securities Fraud Class Action Alert
• Negative Sentiment: The repeated litigation announcements increase headline, financial and reputational risk for Regeneron Pharmaceuticals (REGN). The core concern is that the failed melanoma study could delay or reduce expectations for a key growth opportunity and expose the company to potential damages and legal costs. REGN Investors Securities Fraud Lawsuit Notice

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source